Swisscom Expands Use of RANK Software Amidst Growing Global Security Analyst Shortage
RANK provides Swisscom with real-time threat detection, hunting and integration capabilities
LONDON, Dec. 03, 2018 (GLOBE NEWSWIRE) -- RANK Software today announced that Swisscom, Switzerland’s leading telecoms company, is expanding its relationship with RANK. After working together for several years, Swisscom has signed a new three-year agreement to use RANK Software’s Virtual Advisor to Security Analysts (VASA) AI-based threat detection platform to provide real-time threat hunting capabilities throughout its internal network across its business.
As a major telecommunications provider in Switzerland, Swisscom network traffic exceeds 1 billion events per day. RANK software helps the SOC analysts at Swisscom to assess and investigate cyber security events, allowing them to zero in on the most credible threats. As a result of using VASA by RANK software, Swisscom's security team is able to become more productive and increase the number of alerts resolved per analyst hour.
“With VASA, Swisscom has been able to stay ahead of attacks, leveraging RANK’s flexible and powerful data ingestion capabilities, network analysis and unmatched hunting capabilities,” said Markus Neis, Threat Intelligence Manager at Swisscom.
“Swisscom is not alone in their growing need to extend their threat-hunting capabilities. Companies around the world tell us that they worry about the inefficiencies of sifting through tens of millions of security events each year, wasting time, money, and increasing the chance that a credible threat will slip through the cracks,” said Rick Costanzo, CEO, RANK Software.
VASA helps identify and prevent security threats in real-time by ingesting data from network sources and identifying anomalies for security analysts to review. VASA addresses the challenges of identifying internal and unknown threats commonly missed today by perimeter defense systems through:
Active Learning. RANK Software helps reduce the false positives generated by most AI tools by recoding analyst feedback and allowing them to apply an action to similar alerts. This makes the VASA platform smarter over time allowing security analysts to become more efficient.
Enterprise Scale. RANK Software ingests data from over 40 sources out of the box including System Network Traffic and End Point log files. It is capable of handling more than 1 billion events a day at 10+ gigabits per second.
Contextualization. RANK Software builds on the results of AI, machine learning, and behavioral analytics by making the data more consumable and understanding risk thresholds based on context. This helps assemble and interpret the signals needed to hunt and assess threats faster and with high precision.
- Flexible Architecture. On the cloud or on-premise, RANK Software provides unparalleled context and visibility into potential breaches.
About RANK Software
RANK Software is a leader in security intelligence and analytics. The company’s first product, VASA, is an AI-based threat detection platform that helps enterprises identify and analyze cybersecurity threats in real time, allowing them to take a proactive security posture in the rapidly changing cyber threat landscape. For more information, please visit www.ranksoftwareinc.com.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg saker fra GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra GlobeNewswire
Biome Grow receives new consumer sales amendment from Health Canada for its Nova Scotia brand, Highland Grow17.12.2018 14:00 | Pressemelding
Sales amendment granted for Highland Grow—Amendment to License Significantly Increases Product Availability for Medical and Adult Consumer-Use Markets TORONTO, Dec. 17, 2018 (GLOBE NEWSWIRE) -- Biome Grow Inc. (“Biome” or the “Company”) (CSE: BIO) (Frankfurt: 6OTA) (OTC: ORTFF) is pleased to announce its Nova Scotia-based subsidiary, Highland Grow Inc. (“Highland Grow”), has received its sales authorization via an amendment to its existing license from Health Canada under the Cannabis Act. This authorization will allow Highland Grow to sell cannabis products to end consumers through appropriate medical and recreational cannabis channels, dramatically increasing product availability. The sales authorization will position Biome Grow to serve the rapidly growing domestic and international cannabis markets. "Biome Grow has been steadfast in its focus on a regional business strategy and building provincial brands that can serve the unique requirements of its local cannabis consumers. This n
Alkermes and Biogen Announce Submission of a New Drug Application to U.S. Food and Drug Administration for Diroximel Fumarate in Multiple Sclerosis17.12.2018 13:30 | Pressemelding
DUBLIN, Ireland and CAMBRIDGE, Mass., Dec. 17, 2018 (GLOBE NEWSWIRE) -- Alkermes plc (Nasdaq: ALKS) and Biogen Inc. (Nasdaq: BIIB) today announced that Alkermes has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for diroximel fumarate (BIIB098), a novel oral fumarate in development for the treatment of relapsing forms of multiple sclerosis (MS). Alkermes is seeking approval of diroximel fumarate under the 505(b)(2) regulatory pathway, and the NDA submission includes data from EVOLVE-1, a Phase 3 pivotal trial that evaluated long-term safety in relapsing-remitting MS (RRMS) with approximately 700 patients dosed with diroximel fumarate. If approved, Biogen intends to market diroximel fumarate under the brand name VUMERITY™. This name has been conditionally accepted by the FDA and will be confirmed upon approval. “Diroximel fumarate was designed to provide patients with relapsing forms of multiple sclerosis a novel oral fumarate with a differentiated
SoftServe Documentary Receives “The Best Corporate Media of Ukraine 2018” Award17.12.2018 13:00 | Pressemelding
25th anniversary documentary takes prize in “The Best Corporate Movie” category AUSTIN, Texas, Dec. 17, 2018 (GLOBE NEWSWIRE) -- SoftServe, a leading digital authority and consulting company, announces the Ukrainian Association of Corporate Media, a public organization uniting professionals in the field of marketing, PR, journalism, and advertising, recognized SoftServe in its annual competition – “The Best Corporate Media of Ukraine 2018.” SoftServe’s 25th anniversary documentary took second place in the “The Best Corporate Movie Category.” The documentary honors the company’s 25th anniversary with an inside look at how SoftServe evolved over the past quarter century to become a leading digital authority. In the documentary, SoftServe’s founders and leadership share their inspiring stories and highlight the company’s achievements over the years. “It is a great honor to receive this recognition from the Ukrainian Association of Corporate Media for our 25th anniversary documentary,” sai
Bombardier to supply a further 20 FLEXITY trams to Karlsruhe17.12.2018 10:00 | Pressemelding
Albtal-Verkehrs-Gesellschaft expands its fleet to 62 trams The dual-system vehicles operate on both the tram network and regional railway network BERLIN, Dec. 17, 2018 (GLOBE NEWSWIRE) -- Global mobility solution provider Bombardier Transportation received a call-off order from Albtal-Verkehrs-Gesellschaft mbH (AVG), the transport company of the Alb valley region in southwest Germany, for the delivery of 20 further dual-system BOMBARDIER FLEXITY trams. This third order is based on a framework agreement for a total of 75 vehicles from 2009. The order is valued at approximately 87 million euro ($98 million US). The vehicles will be delivered between May 2020 and March 2021. "Striving to provide attractive local transport services, we have decided to order 20 additional dual-system vehicles from Bombardier Transportation. This will allow us to purposefully enlarge our vehicle fleet offering high-quality standards to our passengers," said Dr. Alexander Pischon, CEO of Albtal-Verkehrs-Gesel
DalCor Announces Completion of Patient Enrollment in dal-GenE, the First Phase 3 Precision Medicine Cardiovascular Outcomes Trial in Coronary Heart Disease17.12.2018 09:00 | Pressemelding
LONDON and MONTREAL, Dec. 17, 2018 (GLOBE NEWSWIRE) -- DalCor today announced the completion of patient enrollment in the dal-GenE study, the first Phase 3 precision medicine cardiovascular outcomes trial in coronary heart disease. The dal-GenE study is evaluating the efficacy of the CETP inhibitor dalcetrapib to reduce clinical cardiovascular events in patients with the AA ADCY9 genotype who have had a recent acute coronary syndrome (ACS). The study has enrolled over 6,000 patients and is being conducted in 680 sites in 32 countries. “The accelerated enrollment of patients in the dal-GenE study reflects the scientific enthusiasm and commitment among the medical community to bring the right medicine to the right patient,” said Dr. Jean-Claude Tardif from the Montreal Heart Institute. “ADCY9 genetic testing to identify the appropriate patients for treatment with dalcetrapib has the potential to provide a genetically targeted therapy to improve clinical outcomes. This approach could pave
Compuware Announces Day One Support for IBM CICS Transaction Server for z/OS V5.514.12.2018 18:02 | Pressemelding